| 000 | 00990 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250515183659.0 | ||
| 264 | 0 | _c20091216 | |
| 008 | 200912s 0 0 eng d | ||
| 022 | _a1875-5453 | ||
| 024 | 7 |
_a10.2174/138920009789375414 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGervasini, Guillermo | |
| 245 | 0 | 0 |
_aPolymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. _h[electronic resource] |
| 260 |
_bCurrent drug metabolism _cJul 2009 |
||
| 300 |
_a547-66 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aMethotrexate _xadverse effects |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 773 | 0 |
_tCurrent drug metabolism _gvol. 10 _gno. 6 _gp. 547-66 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/138920009789375414 _zAvailable from publisher's website |
| 999 |
_c19104551 _d19104551 |
||